2-氨基-3-(4-硝基苯基)丙酸乙酯盐酸盐 | 163251-51-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氨基-3-(4-硝基苯基)丙酸乙酯盐酸盐
• 英文名称: 2-amino-3-(4-nitrophenyl)propionic acid ethyl ester hydrochloride
• 英文别名: 4-nitro-DL-phenylalanine ethyl ester; hydrochloride；4-Nitro-DL-phenylalanin-aethylester; Hydrochlorid；4-nitrophenylalanine ethyl ester hydrochloride；ethyl 2-amino-3-(4-nitrophenyl)propanoate;hydron;chloride
• CAS: 163251-51-2
• 化学式: C₁₁H₁₄N₂O₄*ClH
• 分子量: 274.704
• InChiKey: HHZUMTWHYNIFOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.45
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  98.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-氨基-3-(4-硝基苯基)丙酸乙酯盐酸盐 在 sodium carbonate 作用下， 以 乙酸乙酯 为溶剂， 反应 0.25h， 以89%的产率得到2-氨基-3-(4-硝基苯基)丙酸乙酯
  参考文献：
  名称：

  Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them

  摘要：

  本发明涉及具有化学式（I）的新型抗糖尿病、降血脂、抗肥胖和降胆固醇化合物，其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂化物以及含有它们的药学上可接受的组合物。

  公开号：

  US20030229083A1
• 作为产物：
  描述：

  2-acetylamino-2-(4-nitrobenzyl)malonic acid diethyl ester 在 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 2-氨基-3-(4-硝基苯基)丙酸乙酯盐酸盐
  参考文献：
  名称：

  Anthranilic acid based CCK1 receptor antagonists: preliminary investigation on their second “touch point”

  摘要：

  In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series Of Unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranific acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists. (c) 2005 Elsevier SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2005.01.002

文献信息

• [EN] A PROCESS FOR THE SYNTHESIS OF MELPHALAN<br/>[FR] PROCÉDÉ DE SYNTHÈSE DE MELPHALAN
  申请人：INDENA SPA

  公开号：WO2021130163A1

  公开（公告）日：2021-07-01

  The invention relates to a process for the preparation of Melphalan (4-[bis(2-5 chloroethyl)amino]-L-phenylalanine of formula (I) said process comprising the reaction of a 4-amino-L-phenylalanine protected at the carboxy and amino aminoacidic groups with an agent able to convert the aromatic amino group into a group of formula: -N(CH2CH2OS(O)nO-)2, wherein n is 1 or 2 followed by conversion of the –-N(CH2CH2OS(O)nO-)2 group into a -N(CH2CH2Cl)2 group. The invention also provides novel intermediates useful for the preparation of Melphalan.

  该发明涉及一种用于制备美法仑（4-[双(2-5氯乙基)氨基]-L-苯丙氨酸）的过程，其中所述过程包括将在羧基和氨基氨基团上保护的4-氨基-L-苯丙氨酸与能够将芳香族氨基转化为式子-N(CH2CH2OS(O)nO-)2的试剂发生反应，其中n为1或2，然后将-N(CH2CH2OS(O)nO-)2团转化为-N(CH2CH2Cl)2团。该发明还提供了用于制备美法仑的新型中间体。
• Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them
  申请人：Bhuniya Debnath

  公开号：US20050113368A1

  公开（公告）日：2005-05-26

  The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I) their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds. More particularly, the present invention relates to novel alkyl carboxylic acids of the general, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds. The present invention also relates to processes for the preparation of the compounds of formula (I), novel intermediates, processes for their preparation, their use in the preparation of the above said compounds and their use as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds.

  本发明涉及公式（I）的新型抗糖尿病、降脂、抗肥胖和降胆固醇化合物及其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和包含它们的药学上可接受的组合物，以及制备这些化合物的方法。更具体地说，本发明涉及一般的烷基羧酸及其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和包含它们的药学上可接受的组合物，以及制备这些化合物的方法。本发明还涉及公式（I）化合物的制备方法、新型中间体的制备方法、以及它们在制备上述化合物和作为抗糖尿病、降脂、抗肥胖和降胆固醇化合物的用途。
• COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Debnath Bhuniya

  公开号：US20070142470A1

  公开（公告）日：2007-06-21

  The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

  本发明涉及一种新型抗糖尿病、降脂、抗肥胖和降胆固醇的化合物，其化学式为(I)，其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组合物。
• Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds
  申请人：Bhuniya Debnath

  公开号：US20110105748A1

  公开（公告）日：2011-05-05

  The present invention relates to novel propionic acid derivatives. More particularly, the present invention relates to beta-phenyl alpha-oxysubstituted propionic acids of the general formula (I). The present invention also relates to processes for the preparation of compounds of the formula (I) and their use in the preparation of compounds of formula (II).

  本发明涉及新型丙酸衍生物。更具体地，本发明涉及一般式（I）的β-苯基α-氧代取代丙酸。本发明还涉及制备式（I）化合物的方法及其在制备式（II）化合物中的应用。
• THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0638075B1

  公开（公告）日：2002-01-16